Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome (FLINTLOCK)
NCT07899346 is registered in ClinicalTrials.gov with Invivyd, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome (FLINTLOCK)
- Lead sponsor
- Invivyd, Inc.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- June 30, 2027
- Enrollment
- 130 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
covid 19 vaccine, covid long, covid-19 (sars-cov-2 infection), long covid
Arms
As registered; 2 arms.
-
VYD2311
Dosing via intravenous (IV) infusion on Day 1 follow by dosing via intramuscular (IM) injection on Day 30 and Day 60 with VYD2311
-
Placebo
Dosing via intravenous (IV) infusion on Day 1 follow by dosing via intramuscular (IM) injection on Day 30 and Day 60 with Placebo - 0.9% sodium chloride (normal saline)
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through Day 90
-
Serum concentrations of VYD2311 through Day 90
Lead sponsor's other trials
Invivyd, Inc., most recent start first.
+3 more trials
Similar trials
Same condition (Post-Acute COVID-19 Syndrome) and phase, most recent start first.
+72 more trials See the condition page